Connaissances actuelles et défis de la prise en charge des lymphomes non hodgkiniens en Afrique subsaharienne : revue de la littérature
REVUE DES SCIENCES DE LA SANTE · 2026-08-12 · 5 (2) · 1081-1095
DOI: 10.71004/rss.026.v5.i2.153 ↗Abstract
Non-Hodgkin lymphomas (NHL) constitute a heterogeneous group of lymphoid neoplasms whose global incidence has increased over the past few decades. Advances in our understanding of their biology have profoundly changed their classification, diagnosis, and therapeutic management. This narrative review aims to synthesize recent data on the epidemiology, pathophysiology, diagnosis, prognosis, and treatment of NHL, with a particular focus on the realities of sub-Saharan Africa. A narrative literature review was conducted using the PubMed, ScienceDirect, and ResearchGate databases. Publications in French and English published between 2015 and 2025 were searched using the keywords: “non-Hodgkin lymphoma,” “NHL,” “epidemiology,” “diagnosis,” “treatment,” and “Africa.” Systematic reviews, meta-analyses, randomized clinical trials, major observational studies, and international guidelines were included. A total of 54 studies were selected. NHLs are characterized by recurrent genetic alterations involving, in particular, MYC, BCL2, BCL6, and TP53, as well as by the activation of oncogenic signaling pathways such as NF-κB and PI3K/AKT/mTOR. Diagnosis relies on histology, immunohistochemistry, and molecular biology techniques, including fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS). Prognostic scores such as IPI, FLIPI, and MIPI remain widely used. Targeted therapies, bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cells have improved survival in high-income countries. In sub-Saharan Africa, limited access to specialized diagnostic tools and innovative treatments remains a major obstacle. Despite recent therapeutic advances, significant disparities persist in the management of NHL. Strengthening diagnostic capabilities, improving access to innovative treatments, and developing international collaborations are essential to improving patient outcomes in sub-Saharan Africa.
EUVIMED